Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$40.08MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel W. Paterson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
- Beta
- 0.32
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -7.39
Financials
Revenue
$40.08M+300.8%Net Income
$-34.67MEBITDA
$-33.22MFree Cash Flow
$-43.91MEPS (diluted)
$-0.35Shares Outstanding (diluted)
100.12M+3147.7%Operating Expenses
$68.75MCash & Debt
$136.35MReturn of Capital
$0.00Revenue by Segment (annual)
$5.66MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $30.91M | $-209.47M | $-3.02 |
| 2024 | $10.00M | $-130.64M | $-3.66 |
| 2023 | $0.00 | $-87.37M | $-3.96 |
| 2022 | $2.60M | $-73.81M | $-4.57 |
| 2021 | $2.05M | $-71.20M | $-4.92 |
| 2020 | $88.52M | $-67.73M | $-5.28 |
| 2019 | $17.46M | $-149.21M | $-24.01 |
| 2018 | $26.72M | $-72.43M | $-13.44 |
| 2017 | $0.00 | $-67.80M | $-21.18 |
| 2016 | $0.00 | $-36.44M | $-11.82 |
| 2015 | $0.00 | $-57.87M | $-19.32 |
| 2014 | $0.00 | $-53.37M | $-24.82 |
| 2013 | $0.00 | $-41.20M | $-21.80 |
| 2012 | $0.00 | $-31.98M | $-20.45 |
Valuation
VSTMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
147+109.52%Social Signal Score
Mentions (16)
- Newsseekingalpha.com·2d ago·Positive
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Negative
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III Verastem NASDAQ: VSTM presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. The company also outlined plans for registrational Phase II studies and frontline Phase III trials.
View source ↗ - Newsbarrons.com·3d ago·Negative
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.
View source ↗ - Newsbusinesswire.com·3d ago·Positive
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common sto…
View source ↗ - Newsbusinesswire.com·3d ago·Positive
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will also continue to serve on the Company's Board of Directors. The CEO transition follows t…
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.
View source ↗ - Newszacks.com·5d ago·Positive
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsseekingalpha.com·11d ago·Neutral
Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor, VS-7375, in multiple cancers. Q2 '26 net product revenues reached $25.1M in just the fourth quarter of the launch of Co-pack. An October readout from the TARGET-D 101 trial of VS-7375 in solid tumors represents a significant near-term clinical catalyst.
View source ↗ - Newsbusinesswire.com·11d ago·Positive
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant except…
View source ↗ - Newsbusinesswire.com·15d ago·Neutral
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC.
View source ↗ - Newsbusinesswire.com·18d ago·Positive
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright Verastem NASDAQ: VSTM executives outlined the company's commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic, lung and colorectal cancers.
View source ↗ - Newszacks.com·39d ago·Positive
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
View source ↗ - Newsbusinesswire.com·39d ago·Positive
…Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers…
View source ↗ - Newsbusinesswire.com·45d ago·Positive
Verastem Oncology to Participate in Upcoming September Investor Conferences BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences: Cantor Global Healthcare Conference in New York City: S…
View source ↗ - Newsseekingalpha.com·47d ago·Positive
…stem is evolving from a speculative biotech into a commercially validated precision oncology company, leveraging AVMAPKI FAKZYNJA revenue to fund KRAS G12D programs. VSTM's AVMAPKI FAKZYNJA launch demonstrates strong product-market fit, with $43.7M H1 2026 revenue and growing prescriber adoption in a rare disease market. The October 2026 VS-7375 data update is a pivotal catalyst; positive results could unlock multibillion-dollar KRAS G12D markets in pancreatic, lung, and colorectal cancer.
View source ↗
Earnings
Tue, Nov 3(in 2 weeks)
Consensus estimate $-0.44 per share
Typical surprise +18.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.35 vs $-0.43beat
- Thu, May 7$-0.37 vs $-0.46beat
- Wed, Mar 4$-0.39 vs $-0.49beat
- Tue, Nov 4$-1.35 vs $-0.51miss
- Thu, Aug 7$-0.39 vs $-0.85beat
- Tue, May 13$-0.96 vs $-0.72miss
Estimates and results for VSTM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VSTM officers and directors.
- Bought
- —
- Sold
- $1.9m
0 trades
57 trades
- Paterson Dansold
- Calkins Danielsold
- Calkins Danielsold
- Paterson Dansold
- Paterson Dansold
- Calkins Danielsold
- Calkins Danielsold
- Paterson Dansold
43 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VSTM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.